Literature DB >> 8469349

Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia.

J Jankovic1, K S Schwartz.   

Abstract

We performed a longitudinal analysis of the effects of repeat botulinum toxin (BTX) injections in 42 patients with blepharospasm (BL) and 115 patients with cervical dystonia (CD) who received BTX injections between 1984 and 1992 in at least five separate treatment sessions. Although the BL patients were significantly older (59.8 years) than the CD patients (50.6 years; p < 0.001), there were no other demographic differences between the two groups. While the total dose per treatment session and the peak effect rating remained the same, the duration of benefit increased and the number of complications decreased during the course of treatment. We concluded that chronic treatment with BTX in patients with BL and CD is not associated with any decline in benefit, and that efficacy may improve slightly with repeat treatments.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8469349     DOI: 10.1212/wnl.43.4.834

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

Review 1.  Distal esophageal spasm: an update.

Authors:  Sami R Achem; Lauren B Gerson
Journal:  Curr Gastroenterol Rep       Date:  2013-09

2.  Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

3.  Physical therapy program for cervical dystonia: a study of 20 cases.

Authors:  Mariana Araujo Ribeiro Queiroz; Hsin Fen Chien; Flávio Augusto Sekeff-Sallem; Egberto Reis Barbosa
Journal:  Funct Neurol       Date:  2012 Jul-Sep

4.  Clinical analysis of blepharospasm and apraxia of eyelid opening in patients with parkinsonism.

Authors:  Won Tae Yoon; Eun Joo Chung; Sang Hyeon Lee; Byung Joon Kim; Won Yong Lee
Journal:  J Clin Neurol       Date:  2005-10-20       Impact factor: 3.077

5.  Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia.

Authors:  R Hilker; M Schischniaschvili; M Ghaemi; A Jacobs; J Rudolf
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-08       Impact factor: 10.154

6.  Measuring patient benefit from botulinum toxin in the treatment of dystonia. Feasibility of cost-utility analysis.

Authors:  C M Gudex; M R Hawthorne; A G Butler; P O Duffey
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

7.  Costs of treating dystonias and hemifacial spasm with botulinum toxin A.

Authors:  R C Dodel; A Kirchner; R Koehne-Volland; G Künig; A Ceballos-Baumann; M Naumann; A Brashear; H P Richter; T D Szucs; W H Oertel
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

8.  Position paper on the use of botulinum toxin in cerebral palsy. UK Botulinum Toxin and Cerebral Palsy Working Party.

Authors:  L J Carr; A P Cosgrove; P Gringras; B G Neville
Journal:  Arch Dis Child       Date:  1998-09       Impact factor: 3.791

Review 9.  Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin.

Authors:  L Andrew Koman; Beth Paterson Smith; Rajesh Balkrishnan
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance.

Authors:  J W Brans; I P de Boer; M Aramideh; B W Ongerboer de Visser; J D Speelman
Journal:  J Neurol       Date:  1995-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.